| Autor: |
Schürks M; Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2007 Oct; Vol. 82 (4), pp. 396-401. Date of Electronic Publication: 2007 Mar 14. |
| DOI: |
10.1038/sj.clpt.6100159 |
| Abstrakt: |
Only about 70% of migraine and cluster headache (CH) patients report significant treatment responses to triptans, which are agonists at 5-HT(1B/D) receptors belonging to the family of G protein-coupled receptors. We analyzed whether a common polymorphism in the gene for the G protein beta3 subunit (GNB3 C825T) modulates responder rates to triptans among a cohort of 231 unrelated Caucasian CH patients. A total of 180 CH patients used triptans, of whom 71.1% reported treatment success. The adjusted odds ratio for treatment response to triptans for heterozygous carriers of the GNB3 825T allele was 2.96 (95% confidence interval 1.34-6.56; P=0.0074) vs carriers of the 825CC genotype. The GNB3 genotype status did not affect responses to other acute and preventive therapeutic regimes including oxygen, verapamil, and corticosteroids, i.e., drugs not directly affecting G proteins. We conclude that pain relief by triptans is significantly modulated by a common genetic GNB3 variant. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text